HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer ...

Overnight in the U.S., the three major averages fell following Trump’s attacks on Powell, raising questions about the central ...

Overnight in the U.S., the three major averages fell following Trump’s attacks on Powell, raising questions about the central ...

This is the first CSCO Guidelines recommendation for lisaftoclax (APG-2575), making it the only China-developed Bcl-2 inhibitor recommended in the CSCO Guidelines. This marks a milestone achieved by ...

Davis Polk & Wardwell and King & Wood Mallesons have advised on a few Chinese tea company listings in recent months.